Travere Therapeutics, Inc. (TVTX)

Name: Travere Therapeutics, Inc. (TVTX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001438533 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated CA
Fiscal year ends around Dec 31

For the year ended 2025-12-31, Travere Therapeutics, Inc. reported revenue of $490.73M. Revenue grew 110.5% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $591.33M.

Key ratios (year ended 2025-12-31)

-12.8%

Operating margin

-5.2%

Net margin

-22.2%

Return on year-end equity

110.5%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$591.33M	$490.73M	$233.18M	$145.24M	$109.46M	$131.84M	$198.32M	$175.34M	$164.25M	$154.94M	$133.59M
Cost of Revenue	$8.26M	$10.34M	$7.74M	$11.45M	$4.42M	$3.82M	$6.13M	$5.23M	$5.53M	$3.60M	$4.55M
Gross Profit (computed)	n/a	n/a	n/a	$133.79M	n/a	n/a	n/a	n/a	n/a	n/a	n/a
R&D Expense	$227.14M	$206.01M	$217.50M	$244.99M	$227.33M	$201.16M	$131.77M	$140.96M	$123.76M	$78.17M	$70.82M
Operating Income	-$40.46M	-$62.82M	-$323.83M	-$388.14M	-$319.81M	-$199.43M	-$176.16M	-$137.36M	-$80.04M	-$53.79M	-$58.21M
Depreciation & Amortization	$63.37M	$60.74M	$43.55M	$38.53M	$20.72M	$12.75M	$24.58M	$20.41M	$18.67M	$17.80M	$16.14M
EBITDA	$22.91M	-$2.08M	-$280.27M	-$349.61M	-$299.09M	-$186.68M	-$151.58M	-$116.95M	-$61.37M	-$35.99M	-$42.08M
Net Income	-$43.46M	-$25.55M	-$321.55M	-$111.40M	-$278.48M	-$180.09M	-$169.43M	-$146.43M	-$102.68M	-$59.73M	-$47.90M
EPS (Diluted)	n/a	-$0.29	-$4.08	-$1.50	-$4.37	-$3.01	-$3.56	-$3.46	-$2.54	-$1.54	-$1.29
Total Assets	$799.36M	$605.19M	$594.12M	$788.91M	$672.59M	$776.63M	$607.44M	$604.80M	$709.16M	$520.35M	$525.28M
Total Liabilities	$774.84M	$490.36M	$535.05M	$588.10M	$629.73M	$474.52M	$396.23M	$383.60M	$390.91M	$227.21M	$217.51M
Shareholders' Equity	$24.52M	$114.83M	$59.08M	$200.81M	$42.85M	$302.11M	$211.21M	$221.20M	$318.25M	$293.13M	$307.77M
Cash & Equivalents	$117.73M	$93.03M	$58.53M	$58.18M	$61.69M	$165.75M	$84.77M	$62.44M	$102.87M	$99.39M	$41.00M
Operating Cash Flow	$92.70M	$37.78M	-$237.47M	-$280.02M	-$186.29M	-$14.79M	-$42.74M	-$58.21M	-$24.96M	$7.40M	-$3.44M
Capital Expenditures	n/a	n/a	n/a	$668.0K	$191.0K	$5.10M	$6.77M	$195.0K	$727.0K	$887.0K	$1.43M
Free Cash Flow	n/a	n/a	n/a	-$280.69M	-$186.48M	-$19.89M	-$49.51M	-$58.41M	-$25.68M	$6.52M	-$4.87M
Share Repurchases	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$0
Shares Outstanding	94.17M	90.92M	87.45M	75.37M	64.29M	62.49M	52.25M	43.09M	41.39M	39.37M	37.91M
Weighted Average Diluted Shares	n/a	89.21M	78.89M	74.27M	63.76M	59.83M	47.54M	42.34M	40.43M	38.77M	38.29M
EPS (Basic)	n/a	-$0.29	-$4.08	-$1.50	-$4.37	-$3.01	-$3.56	-$3.46	-$2.54	-$1.54	-$1.29

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView